To foster interdisciplinary collaboration and knowledge sharing, and to integrate the professional expertise and resources of both

 academic and corporate entities to advance the field of CAR-M cell therapy for solid tumors, on June 8th, RocRock Biotech Co., Ltd. and

 Shandong Port Medical and Health Management Group held a signing ceremony at Qingdao Fuwai Hospital. During this event,

 Professor Yin Xiushan, co-founder and CEO of Kunshi Biotech, was appointed as a distinguished expert in scientific research and 

regenerative medicine.

In attendance at the signing ceremony were:

- Yin Xiushan, CEO of Kunshi Biotech, and members of the scientific research team from Kunshi Biotech,

- Pang Jinhua, Party Committee Secretary and Chairman of the Shandong Port Medical and Health Management Group,

- Yu Chao, Deputy Party Committee Secretary and General Manager of the Shandong Port Medical and Health Management Group,

- Li Jiongji, Deputy Party Committee Secretary of the Shandong Port Medical and Health Management Group, and Party Committee Secretary and Chairman of Qingdao Fuwai Hospital.

(Signing ceremony)

At the meeting, the two parties agreed on key areas in scientific research and regenerative medicine, laying the groundwork for a comprehensive partnership. They aim to enhance research capabilities, innovate new technologies for treating CAR-M solid tumors, and advance medical techniques in cellular molecular biology and genetic testing. This collaboration significantly strengthens the foundation for developing cell pharmaceuticals targeting solid tumors. By sharing resources and working together, both sides can expedite experiments and data analysis, thereby increasing research efficiency and accelerating the development and clinical application of cell therapies for solid tumors.

(Negotiation and signing)

After the signing event, the two sides carried out a field visit to discuss the development and location selection for the comprehensive cell resource library. CEO Yin Xiushan of Kunshi Biotech provided valuable input and recommendations for the construction of the integrated cell laboratory and the progression of future scientific research endeavors.

(Signed special experts)

The signing ceremony signifies the commencement of a new chapter in the collaborative journey between the two parties, aiming to shape a shared future. Moving forward, they are set to expedite the development of an Integrated Cell Resource Library, encompassing the establishment of Regional Cell Storage Centers, Cell Preparation Centers, Cell Tissue Engineering Centers, Bio-Sample Library Centers, and Genetic Engineering Centers—the "five key centers." This initiative is designed to stimulate the healthy and swift growth of the cell therapy and regenerative medicine sectors. In partnership with the Shandong Medical and Health Group, Kunshi Biotech will gain insights into clinical demands and the therapeutic hurdles faced by patients, enabling the targeted development and refinement of cell Drug therapy strategies. This profound collaboration promises an expansion of clinical trial opportunities and a hastened progression of cell drugs from development to market application. By pooling resources, sharing knowledge, and fostering interdisciplinary collaboration, the translation of cell drug research outcomes for solid tumors into clinical practice is expedited. This approach is expected to invigorate innovation and advancement in the treatment of solid tumors, offering patients a broader array of effective treatment options and contributing to the evolution of medical technology.

About Shandong Port Group

 Shandong Port Group Co., Ltd., a crucial state-owned enterprise under the provincial government, was founded on August 6, 2019, and is headquartered in Qingdao, Shandong Province. It operates four major port conglomerates—Qingdao Port Group, Rizhao Port Group, Yantai Port Group, and Bohai Bay Port Group—as well as three publicly traded companies: Qingdao Port (ticker symbols 601298.SH and 06198.HK), Rizhao Port (ticker symbol 600017.SH), and Rizhao Port Yulong (ticker symbol 6117.HK). The group also includes thirteen specialized divisions spanning investment control, harbor development, urban-industrial integration, logistics, shipping, cruise tourism, machinery, trade, technology, international expansion, vocational education, healthcare, and port services. The group has established an integrated development framework led by Qingdao Port, flanked by Rizhao and Yantai Ports, extended by Bohai Bay Port, supported by its various divisions, and backed by a network of inland ports. In 2022, it achieved a cargo throughput surpassing 1.6 billion tons and a container volume exceeding 37 million TEUs. Committed to a bidirectional, east-west strategy and integrating land and sea efforts, Shandong Port Group is dedicated to constructing a premier marine port that spans across the oceans and reaches into every corner of the land, earning a global reputation and shining on the world stage.

About Shandong Port Medical Care Health Management Group

(Shandong Port Medical Care Health Management Group)

Shandong Port Medical and Health Management Group Co., Ltd., a state-owned conglomerate founded by Shandong Port Group, encompasses an array of medical and health services including healthcare, rehabilitation, health management, and elderly care. The group operates under brands such as Qingdao Fuwai Cardiovascular and Thoracic Hospital—a top-tier specialty facility—alongside Rizhao Port Hospital and Yantai Port Hospital, both of which are second-tier general hospitals. Boasting over 1800 available beds and a team of 360 senior professionals, the group excels in specialized fields like cardiology, rehabilitation, orthopedics, urology, general surgery, neurology, ophthalmology, and health management, catering to an annual outpatient and emergency volume of 1 million visits, with 50,000 patient discharges and the execution of 30,000 surgical procedures. This group stands as a model harbor healthcare provider, prioritizing medical services, bolstered by health management, and oriented towards elderly care.